Research programme: epitope-based vaccines - EpiVax Oncology

Drug Profile

Research programme: epitope-based vaccines - EpiVax Oncology

Latest Information Update: 28 Sep 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EpiVax Oncology
  • Class Antineoplastics; Epitopes; Vaccines
  • Mechanism of Action T-cell receptor antigen agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 12 Jun 2018 EpiVax Oncology announces intention to submit IND to US FDA for Cancer at the end of 2018
  • 25 Sep 2017 Preclinical trials in Cancer in USA (Parenteral)
  • 25 Sep 2017 EpiVax Oncology plans a phase Ib trial for Bladder cancer and Malignant melanoma (Parenteral) in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top